Suprasert Prapaporn, Khunamornpong Surapan
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
J Med Assoc Thai. 2010 May;93(5):608-12.
The occurrence of uterine cancer in breast cancer patients who received tamoxifen treatment, is well described. 72 our knowledge, an association between uterine anomaly and uterine carcinosarcoma in these patients had not been reported. We present a case of uterine carcinosarcoma occurring in uterine didelphys of a 72-year-old breast cancer patient, who had been treated with tamoxifen for 5 years. The patient presented with large pelvic mass. The uterine anomaly was not recognized preoperatively. The patient died of disease 5 months after diagnosis. Postmenopausal women taking tamoxifen should be closely monitored for symptoms of endometrial lesions.
接受他莫昔芬治疗的乳腺癌患者发生子宫癌的情况已有充分描述。据我们所知,这些患者中子宫异常与子宫癌肉瘤之间的关联尚未见报道。我们报告一例72岁乳腺癌患者,其双子宫发生子宫癌肉瘤,该患者接受他莫昔芬治疗5年。患者表现为盆腔巨大肿块。术前未识别出子宫异常。患者在诊断后5个月死于疾病。服用他莫昔芬的绝经后妇女应密切监测子宫内膜病变的症状。